Neuren Pharmaceuticals welcomes milestone approval for Daybu
Neuren Pharmaceuticals has received positive news for the proposed marketing of the Daybu treatment of Rett syndrome.
Market Cap $10.95B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
